Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBX0101 in painful osteoarthritis of the knee
NCT03513016Phase 1Completed
- Sponsor
- Unity Biotechnology
- Start
- May 2018
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of UBX0101 in osteoarthritis (OA) (4 arms), sponsored by Unity Biotechnology. Primary endpoint: Incidence of serious and non-serious adverse events at 12 weeks. Started May 2018; status: completed.
02
Drugs
UBX0101
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03513016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03513016.